{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:44Z","timestamp":1784408864216,"version":"3.55.0"},"reference-count":33,"publisher":"Kurume Medical Journal","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.2739\/kurumemedj.ms7134008","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T18:07:45Z","timestamp":1749751665000},"page":"167-173","source":"Crossref","is-referenced-by-count":2,"title":["Development of Thyrotoxicosis With Positive TSH Receptor Antibody and Transition to Hypothyroidism in a Patient With Unresectable Hepatocellular Carcinoma During Combined Atezolizumab and Bevacizumab Therapy: A Case Report and Review of the Literature"],"prefix":"10.2739","volume":"71","author":[{"given":"RYUTARO","family":"HIDAKA","sequence":"first","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUJI","family":"HIROMATSU","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NARIHITO","family":"TATSUMOTO","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKAHIRO","family":"FUKUYAMA","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOKO","family":"SAGARA","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AIRA","family":"UCHIDA","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIDEKAZU","family":"TAMAI","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MASAYUKI","family":"TOJIKUBO","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUKO","family":"AKEHI","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EIJI","family":"KAWASAKI","sequence":"additional","affiliation":[{"name":"Diabetes, Thyroid, and Endocrine Center, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROKI","family":"NAKAMURA","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shin Koga Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1445","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Iwama S, Kobayashi T, Yasuda Y, and Arima H. Immune checkpoint inhibitor-related thyroid dysfunction. Best Pract Res Clin Endocrinol Metab 2022; 36:101660.","DOI":"10.1016\/j.beem.2022.101660"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Peiffert M, Cugnet-Anceau C, Dalle S, Chikh K, Assaad S et al. Graves\u2019 disease during immune checkpoint inhibitor therapy (a case series and literature review). Cancers (Basel) 2021; 13:1944. doi: 10.3390\/cancers13081944","DOI":"10.3390\/cancers13081944"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Koizumi Y, Hirooka M, Hiraoka A, Ochi H, Tanaka T et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocr J 2019; 66:787-792.","DOI":"10.1507\/endocrj.EJ19-0140"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382:1894-1905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Muir CA, Menzies AM, Clifton-Bligh R, and Tsang VHM. Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer. Thyroid 2020; 30:1458-1469.","DOI":"10.1089\/thy.2020.0032"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ichimura T, Ichikura D, Hinata M, Hida N, and Baba T. Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series. SAGE Open Med Case Rep 2023; 11: 2050313X231164488.","DOI":"10.1177\/2050313X231164488"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 2016; 101:4431-4439.","DOI":"10.1210\/jc.2016-2300"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Azmat U, Liebner D, Joehlin-Price A, Agrawal A, and Nabhan F. Treatment of ipilimumab induced Graves\u2019 disease in a patient with metastatic melanoma. Case Rep Endocrinol 2016; 2016:2087525.","DOI":"10.1155\/2016\/2087525"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gan EH, Mitchell AL, Plummer R, Pearce S, and Perros P. Tremelimumab-induced Graves hyperthyroidism. Eur Thyroid J 2027; 6:167-170.","DOI":"10.1159\/000464285"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Brancatella A, Viola N, Brogioni S, Montanelli L, Sardella C et al. Graves\u2019 disease induced by immune checkpoint inhibitors: A case report and review of the literature. Eur Thyroid J 2019; 8:192-195.","DOI":"10.1159\/000501824"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Iadarola C, Croce L, Quaquarini E, Teragni C, Pinto S et al. Nivolumab induced thyroid dysfunction: unusual clinical presentation and challenging diagnosis. Front Endocrinol (Lausanne) 2019; 9:813.","DOI":"10.3389\/fendo.2018.00813"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Narayen G and Lieb D. SAT-584 pembrolizumab-related Graves\u2019 disease: a rare adverse effect of an anti-PD-1 antibody cancer immunotherapy. J Endocr Soc 2019; 3 (Suppl 1):SAT-584.","DOI":"10.1210\/js.2019-SAT-584"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yajima K and Akise Y. A case report of Graves\u2019 disease induced by the ati-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient. Case Rep Endocrinol 2019; 2019:2314032.","DOI":"10.1155\/2019\/2314032"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yamada H, Okajima F, Onda T, Fujimori S, Emoto N et al. New-onset Graves\u2019 disease after the initiation of nivolumab therapy for gastric cancer: a case report. BMC Endocr Disord 2020; 20:132.","DOI":"10.1186\/s12902-020-00613-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kurihara S, Oikawa Y, Nakajima R, Satomura A, Tanaka R et al. Simultaneous development of Graves\u2019 disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report. J Diabetes Investig 2020; 11:1006-1009.","DOI":"10.1111\/jdi.13212"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ueba Y, Yamauchi I, Hakata T, Fujita H, Okamoto K et al. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study. Endocr J 2023; 70:323-332.","DOI":"10.1507\/endocrj.EJ22-0467"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Alqaisi S and Rahman A. A rare case of pembrolizumab-associated Graves\u2019 Disease. Cureus 2023; 15:e34696.","DOI":"10.7759\/cureus.34696"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr Surg 2019; 35:50-52.","DOI":"10.1097\/IOP.0000000000001161"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Reddy C and Zena M. Case of hyperthyroidism in a patient on anti-PD-1 (programmed cell death receptor-1 blocking antibody) therapy caused by destructive thyroiditis followed by Graves\u2019 disease. J Endocr Soc 2021; 5:A968-A969. doi:10.1210\/jendso\/bvab048.1979","DOI":"10.1210\/jendso\/bvab048.1979"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Borodic G, Hinkle DM, and Cia Y. Drug-induced Graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 2011; 27:e87-e88.","DOI":"10.1097\/IOP.0b013e3181ef72a1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Min L, Vaidya A, and Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164:303-307.","DOI":"10.1530\/EJE-10-0833"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. McElnea E, Mh\u00e9al\u00f3id \u00c1N, Moran S. Kelly R, and Fulcher T. Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab. Orbit 2014; 33:424-427.","DOI":"10.3109\/01676830.2014.949792"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Park ES, Rabinowits G, Hamnvik O-PR, and Dagi LR. A case of Graves\u2019 ophthalmopathy associated with pembrolizumab (keytruda) therapy. J Am Assoc Pediatr Ophthalmol Strabismus 2018; 22:310-312.","DOI":"10.1016\/j.jaapos.2018.01.006"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Campredon P, Imbert P, Mouly C, Grunenwald S, Mazi\u00e8res J et al. Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment. Eur Thyroid J 2018; 7:84-87.","DOI":"10.1159\/000485742"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sabini E, Sframeli A, and Marin\u00f2 M. A case of drug-induced Graves\u2019 orbitopathy after combination therapy with tremelimumab and durvalumab. J Endocrinol Invest 2018; 41:877-878.","DOI":"10.1007\/s40618-018-0906-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Oyibo SO and Mahgoub MO. Atezolizumab-induced hypothyroidism in a patient with pre-existing triiodothyronine (T3) thyrotoxicosis due to Graves\u2019 disease: a case report and literature review. Cureus 2021; 13:e19736.","DOI":"10.7759\/cureus.19736"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 2020; 31:724-744.","DOI":"10.1016\/j.annonc.2020.03.285"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 2019; 14:e0216954.","DOI":"10.1371\/journal.pone.0216954"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kotwal A, Kottschade L, and Ryder M. PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 2020; 30:177-184.","DOI":"10.1089\/thy.2019.0250"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Baek HS, Jeong C, Shin K, Lee J, Suh H et al. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. BMC Endocr Disord 2022; 22:89.","DOI":"10.1186\/s12902-022-01004-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 2010; 57:873-880.","DOI":"10.1507\/endocrj.K10E-130"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Okada N, Iwama S, Okuji T, Kobayashi T, Yasuda Y et al. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer 2020; 122:771-777.","DOI":"10.1038\/s41416-020-0736-7"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M et al. Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J Clin Endocrinol Metab 2022; 107:e1620-e1630.","DOI":"10.1210\/clinem\/dgab829"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/71\/3.4\/71_MS7134008\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:41:24Z","timestamp":1763181684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/71\/3.4\/71_MS7134008\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":33,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms7134008","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"value":"0023-5679","type":"print"},{"value":"1881-2090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"article-number":"MS7134008"}}